Objective: To evaluate and validate the incremental value of copeptin in the prediction of outcome and complications as compared with established clinical variables.
Accurate and prompt prediction of functional outcome, mortality, and complications in patients with ischemic stroke is essential for patients, families, and clinicians. In this context, rapidly measurable and reliable blood biomarkers may refine clinical decision-making. Several blood biomarkers have shown the potential to predict outcome after ischemic stroke. However, to be useful in clinical routine, blood biomarkers are expected to improve the prognostic accuracy of established clinical variables such as stroke severity and age. 1 At present, the investigated biomarkers have either failed to further improve prognostication after stroke, or they have not been studied for their additional prognostic value. 1,2 However, a recent single-center study showed that copeptin, a hypothalamic hormone derived from the precursor of vasopressin, predicted outcome and mortality 3 months and 1 year after ischemic stroke, improving the prognostic accuracy of established predictors. 3, 4 Copeptin is a reliable prognostic marker not only in stroke patients but also in patients with cardiovascular events. 5, 6 However, before implementing copeptin in clinical practice, the prognostic potential of copeptin needs to be validated in a prospective, independent, large, multicenter study. Moreover, it is unclear whether copeptin predicts outcome in patients with ischemic stroke that has been treated differently, i.e., conservatively or with thrombolysis. The CoRisk study aimed to validate in a multicenter, international setting the accuracy of copeptin in predicting functional outcome, mortality, and complications as compared with established clinical variables.
METHODS Ethics statement. This study (ClinicalTrials. gov: unique identifier NCT00878813, http://www.clinicaltrials. gov/ct2/show/NCT00878813) was conducted according to the principles expressed in the Declaration of Helsinki and it was approved by the Ethics Committees. All patients or their welfare guardians provided written informed consent for the collection of data, blood samples, and subsequent analyses.
Study design and cohort description. The primary design of this multicenter, prospective, cohort study has been described in detail previously. 7 For the analysis of this study, we included 788 patients older than 18 years with an acute ischemic stroke within 24 hours of symptom onset, admitted consecutively to the emergency department of each tertiary care center between March 24, 2009 and April 8, 2011.
We defined acute ischemic stroke according to the World Health Organization criteria as an acute focal neurologic deficit lasting longer than 24 hours 8 with no sign of acute intracranial bleeding on cerebral imaging. Exclusion criteria were missing informed consent or any diagnosis different from ischemic stroke (i.e., stroke mimics). Stroke physicians prospectively recorded the NIH Stroke Scale (NIHSS) 9 score upon admission. The clinical stroke syndrome was assessed according to the Oxfordshire Community Stroke Project classification. 10 CT or MRI was performed upon admission. MRI with diffusion-weighted imaging was performed in 537 stroke patients. Diffusion-weighted imaging lesion volumes were measured by the consensus of 2 experienced raters unaware of the clinical and laboratory findings. The lesion size was calculated by a frequently used semiquantitative method validated for ischemic stroke lesions. 11 Lesions were categorized into 3 size classes to represent typical stroke patterns: 1) small lesion with a volume of ,10 mm 3 , 2) medium lesion of 10-100 mm 3 , and 3) large lesion with a volume of .100 mm 3 . 3 Detailed information such as cardiac and neurovascular ultrasound and 24-hour EKGs were collected to define stroke etiology according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification. 12 Comorbidities were assessed on admission by the modified Charlson Comorbidity Index. 13 Biomarker measurement. For all patients, blood was drawn in the emergency room and within 24 hours of symptom onset. After centrifugation for 20 minutes at 3,000g at room temperature, plasma (from EDTA tube) was aliquoted. Tubes were frozen locally at each center at 270°C. Copeptin levels were assessed in plasma in a blinded batch analysis by a new chemiluminescence sandwich immunoassay. The lower detection limit was 0.4 pmol/L and the functional assay sensitivity was ,1 pmol/L (,20% interassay coefficient of variation, defined as the ratio of the SD to the mean). In 359 healthy individuals, median copeptin levels were reported to be 4.2 pmol/L with a 99th percentile of 13.5 pmol/L. 14 
Ascertainment of outcomes.
Trained stroke physicians and study nurses assessed outcome 3 months after the acute stroke, either during an outpatient visit (patients who underwent thrombolysis) or with a structured follow-up telephone interview. They were blinded to copeptin levels and baseline clinical variables.
Primary end points. The 2 primary end points were 1) unfavorable functional outcome (including mortality) defined as a modified Rankin Scale (mRS) score of 3 to 6, and 2) mortality within 90 days of hospital admission.
Secondary end point. The secondary outcome included any of the following prespecified 7 complications during hospital stay: symptomatic intracerebral hemorrhage according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study criteria, 15 space-occupying cerebral edema, pneumonia (defined as auscultatory respiratory crackles combined with body temperature $38°C, purulent sputum, or positive chest radiograph), seizures (clinical diagnosis of focal and/or generalized seizure in a previously nonepileptic patient), or mortality within 10 days from stroke onset.
Statistical analysis. Univariate analysis. Statistical analysis was
performed for the primary and secondary end points separately. Discrete variables were expressed as counts (percentages) and continuous variables as means 6 SD or medians (interquartile range [IQR]), depending on their distribution. The distribution of raw biomarker data was skewed. After log transformation with a base of 10, the distribution of the biomarker data approximated a normal distribution. Comparisons for categorical baseline measurements were performed by Fisher exact test and for continuous, not normally distributed baseline data, by the Mann-Whitney U test. For survival analysis, we stratified patients according to copeptin tertiles in Kaplan-Meier curves and compared the groups by means of the log-rank test.
Multivariate regression models. To assess the independent association of copeptin with functional outcome and time to fatal outcome within 3 months, we computed a multivariate logistic and Cox regression model, respectively. We prespecified that models were adjusted for NIHSS score, age, lesion size, modified Charlson Index, 13 and total anterior circulation stroke 10 based on the results of the previous derivation study. 3 In addition, the final multivariate models included variables significantly associated with an unfavorable outcome or mortality in the univariate analyses. Because patients with severe stroke tend to present earlier, time from symptom onset to blood collection was included in the final model. 16 We report odds ratios (ORs) and hazard ratios (HRs) along with 95% confidence intervals (CIs) as measure of association and uncertainty, respectively. OR and HR correspond to a 1-unit increase in the explanatory variable and to any 10-fold increase in copeptin, glucose, or C-reactive protein (CRP) levels (log-transformed with a base of 10). Goodness-of-fit of the multivariate logistic and Cox regression models were assessed with the Hosmer-Lemeshow test and Groennesby and Borgan test, respectively.
Interaction analysis. We further included interaction terms to investigate whether the predictive value of copeptin is modified by treatment status (conservative vs thrombolysis), sex, age, stroke severity (NIHSS scores 0-6, 7-15, and .15), time from symptom onset, blood collection (dichotomized at 4.5 hours), arterial hypertension, diabetes mellitus, and atrial fibrillation. Selection of variables that were tested for interaction was based on biological plausibility on factors that might influence the prognostic value of copeptin. NIHSS was categorized in order to represent clinically relevant stroke severity subgroups (mild, moderate, and severe strokes), and time from symptom onset was dichotomized to represent the time window for IV thrombolysis.
C-statistics. The discriminatory value of copeptin was assessed with the area under the receiver operating characteristic (ROC) curve (AUC). The incremental discriminatory value of copeptin was tested by comparing the AUC of the NIHSS (nested model), our prespecified prognostic factor of reference, 7 with the AUC of the NIHSS and copeptin (whole model), as well as comparing the logistic and Cox regression models without copeptin (nested models) with the same models with copeptin (whole models). For these comparisons of nested to whole models, we used the likelihood ratio test as recommended. 17 Reclassification tables. For risk model of comparison, we used the multivariate models described above. As recommended in the statistical literature, 18 we calculated continuous (categoryfree) net reclassification improvement (NRI) values because our multivariate models of comparisons have no validated risk categories. To calculate category-based NRI values, we used the validated prognostic index by König et al., 19 encompassing admission NIHSS score and age. Four risk categories were chosen: 0%-5%, 5%-10%, 10%-15%, and .15%.
Statistics The detailed patient flow is outlined in figure 1.
The median age of the cohort was 71.0 years (IQR 60.5-80.0), and 38.1% of the patients were women. The most common cardiovascular risk factor was arterial hypertension, which was present in 68.8% of patients. At admission, the median NIHSS score was 6 (IQR 3-13), and the median copeptin concentration was 14.2 pmol/L (IQR 5.9-46.5) (table 1) .
Primary end points. Prediction of functional outcome after 3 months. A total of 300 patients (38.3%) had an unfavorable outcome after 3 months. Median copeptin concentration was more than 3-fold higher in patients with unfavorable outcomes than in those with favorable outcomes (table 1, figure e-1 on the Neurology ® Web site at www.neurology.org). In the multivariate logistic regression model, higher copeptin concentrations independently predicted an unfavorable outcome (adjusted OR for any 10-fold copeptin increase 2.17 [95% CI, 1.46-3.22]). For instance, for a patient with a copeptin level of 30.0 pmol/L, the odds of unfavorable outcome are on average 2.17 times or 117% higher compared with a patient with a copeptin level of 3.0 pmol/L, after adjustment for the covariates included in the logistic regression model presented in table 2. The multivariate logistic model was well calibrated as assessed by the Hosmer and Lemeshow goodness-of-fit test (p 5 0.62).
The discriminatory accuracy of copeptin, assessed with the area under the ROC curve, was 0.71 (95% CI, 0.67-0.75). Copeptin significantly improved the discriminatory accuracy of the NIHSS and the multivariate logistic regression model both for an unfavorable 19 with a categorical NRI of 11.8% (table e-2) . Among patients with a favorable outcome, a total of 11.8% were correctly moved to lower risk categories, whereas in patients with an unfavorable outcome, zero were reclassified. Moreover, adding copeptin to the full model improved reclassification as evidenced by the continuous NRI of 46.8%.
Prediction of mortality within 3 months after stroke. A total of 118 patients (15.1%) died within 3 months after stroke. The median copeptin concentration was more than 5-fold higher in patients who died within (table 3) . These results were also confirmed in reclassification statistics where the categorical NRI of copeptin on the validated prognostic index of König et al. was 37.2% (table e-4). Among survivors, 33.0% were correctly moved to lower risk categories, whereas in nonsurvivors 4.2% were correctly moved to higher risk categories. Moreover, adding copeptin to the multivariate model resulted in a continuous NRI of 64.5%.
Interaction analysis. The predictive value of copeptin regarding functional outcome and mortality was consistent across all subgroups. We did not identify any significant effect modifiers.
Secondary end point: Prediction of complications. A total of 185 patients (23.6%) had at least 1 of the 5 predefined complications during hospitalization. Median copeptin levels were more than 3-fold higher in patients developing any of the prespecified complications during hospitalization (39.9 pmol/L [IQR 16.4-114.0] vs 11.0 pmol/L [IQR 5.3-32.5], p , 0.001) (table e-5). In the multivariate logistic model, copeptin independently predicted the occurrence of at least 1 complication (adjusted OR for any 10-fold copeptin increase 1.93 [95% CI, 1.33-2.80], p 5 0.001). Other significant predictors were the NIHSS score and age. Copeptin improved the prognostic accuracy of the NIHSS (AUC change from 0.79 [95% CI, 0.76-0.83] to 0.80 [95% CI, 0.77-0.84], p 5 0.001). We found no significant interaction between copeptin and each of the potentially effect-modifying variables used for the primary outcomes. Prediction of individual complications was associated with different OR for any 10-fold copeptin increase: for symptomatic intracerebral hemorrhage, OR 1.07 (95% CI, 0.45-2.53, p 5 0.89); for spaceoccupying cerebral edema, OR 2.85 (95% CI, 1.39-5.87, p 5 0.004); for pneumonia, OR 1.79 (95% CI, 1.16-2.76, p 5 0.009); for seizures, OR 1.20 (95% CI, 0.62-2.33, p 5 0.59); and for mortality within 10 days from admission, OR 3.00 (95% CI, 1.67-5.39, p , 0.001). DISCUSSION In this prospective, multicenter study, higher copeptin blood levels independently predicted functional outcome and mortality 3 months after ischemic stroke. Copeptin improved the discriminatory ability of the NIHSS and multivariate models as shown by an increase in the respective AUCs. Despite the modest size of the AUC increases, copeptin improved risk classification by 11.8% for functional outcome and by 37.2% for mortality compared with the validated prognostic index by König et al., 19 encompassing NIHSS score and age. Moreover, copeptin improved reclassification compared with the multivariate models including demographic factors, cardiovascular risk factors, lesion size in MRI, comorbidities, and admission laboratory variables such as CRP and glucose. The CoRisk study confirms and extends the conclusions of the previously published derivation study. 3 Further new findings are that 1) copeptin independently predicts complications, and 2) the prognostic ability of copeptin was consistent across subgroups including different acute treatments (conservative vs thrombolysis).
c Kidney impairment was defined as eGFR ,60 mL/min/1.73 m 2 . 40 d Time to blood collection was calculated in hours from symptom onset (if known). e eGFR was estimated according to the Modification of Diet in Renal Disease Study. 40 f Percentages refer to patients for whom information on DWI lesion was present (n 5 537). Of the 537 patients undergoing an MRI on admission, 371 had a favorable outcome (69.1%) and 166 had an unfavorable outcome (30.9%) within 3 months after stroke. The definition of stroke required an acute focal neurologic deficit lasting longer than 24 hours, suggestive of acute stroke, and with no sign of acute intracranial bleeding on cerebral imaging (CT or MRI). A visible ischemic lesion on MRI was not required for the diagnosis of ischemic stroke.
Although several markers, such as N-terminal brain natriuretic peptide, 5,20,21 CRP, 21-24 D-dimers, 20, 25, 26 interleukin-6, 21, 24, 27 von Willebrand factor, 28, 29 S-100b, 30 and neuron-specific enolase, 31 have been associated with functional outcome or mortality, only a few biomarkers added to prognosis based on clinical assessment. None of these markers, however, were fully evaluated including assessment of accuracy (i.e., calibration by goodness-of-fit test), discriminatory ability (i.e., C-statistics), reclassification improvement, and performance in an external validation study according to the recommendations of the American Heart Association for studies evaluating biomarkers in cardiovascular research. 32 Several prognostic models have been evaluated in the past years. Some of these models include information from MRI 33 or CT 34 ; others are based mostly on clinical information such as comorbidities or stroke severity. [35] [36] [37] As reference for reclassification, we chose the prognostic index of König et al. 19 because of its validation for both functional outcome and mortality at 3 months along with its robust prognostic power arising from 2 easily accessible variables such as age and NIHSS score. To be used in clinical routine, prognosis should be almost immediate and based on only a few variables, thus copeptin, which adds to the simple and highly accurate prognostic index by König et al., 19 may be promising. Measurement of copeptin in the emergency setting (incubation time 30 minutes 6 ) may help physicians to more accurately inform patients and caregivers on the overall prognosis. Copeptin might help in early decisionmaking on aggressiveness of care, potential new interventions, discharge planning, and rehabilitation. In the setting of trials of new stroke therapies, it might also be valuable to predict those with stroke recovery. For optimal risk stratification, it is crucial that prognostic information be available within the first hours from symptom onset, and copeptin meets this demand. The pathophysiologic mechanism relating copeptin with stroke outcome and mortality is only partially understood. Copeptin derives from a larger precursor peptide along with arginine vasopressin (AVP) and is released in an equimolar ratio to AVP. The advantage of copeptin is that it is more stable in blood circulation and easier to measure compared with AVP. 14 The secretion of AVP can be stimulated through brainstem and limbic pathways triggered by different "stressors"; it seems to act as an endogenous barometer of integral homeostasis. Thus, copeptin assesses the severity of damage beyond lesion size, the effect of age, sex, and measurable clinical impairment on admission. In addition AVP/copeptin might be associated with adrenocorticotropic hormone-induced hypercortisolism, which is thought to potentiate ischemic neuronal injury, especially in the long run. 38 Data from experimental studies imply that AVP has a role in brain edema formation because blocking of AVP receptors attenuates brain edema in ischemic mice models. 39 Some limitations of the study merit attention. To assess complications, a time-to-event analysis would have been ideal. However, we were not able to document the exact time of onset of some complications, e.g., aspiration pneumonia, and we did not take into account the duration of hospitalization. Moreover, this study was powered only for the combined end point of complications after stroke, but not to assess each complication separately: our subgroup analyses should be interpreted with caution, and further studies are needed to elucidate the specific association with each of the assessed complications.
In patients with ischemic stroke, copeptin is a validated blood marker that adds predictive information on functional outcome and mortality at 3 months beyond important clinical variables such as stroke severity and age. Copeptin seems to be a promising blood marker for prediction of in-hospital complications.
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